| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 7,608 | 8,699 | 9,175 | -7,676 |
| Research and development | 45,874 | 43,469 | 40,622 | 41,197 |
| General and administrative | 18,087 | 17,989 | 18,357 | 15,042 |
| Total operating expenses | 63,961 | 61,458 | 58,979 | 56,239 |
| Loss from operations | -56,353 | -52,759 | -49,804 | -63,915 |
| Interest income | 2,177 | 2,372 | 2,875 | - |
| Other income (expense), net | 324 | -82 | 51 | 337 |
| Investment income, interest and dividend, total | - | - | - | 1,798 |
| Total other income, net | 2,501 | 2,290 | 2,926 | 2,135 |
| Loss before income taxes | -53,852 | -50,469 | -46,878 | -61,780 |
| Income tax benefit (provision) | 0 | 0 | - | - |
| Net loss | -53,852 | -50,469 | -46,878 | -61,780 |
| Foreign currency translation | -29 | 43 | 58 | 120 |
| Comprehensive loss | -53,881 | -50,426 | -46,820 | -61,660 |
| Earnings per share, basic, total | -0.32 | -0.31 | -0.29 | -0.47 |
| Earnings per share, diluted, total | -0.32 | -0.31 | -0.29 | -0.47 |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic | 167,739,208 | 163,987,640 | 162,527,026 | 132,563,467 |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted | 167,739,208 | 163,987,640 | 162,527,026 | 132,563,467 |
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)